Phase II Randomized, Placebo-controlled Trial of Green Tea Extract in Patients with High-risk Oral Premalignant Lesions

Epidemiologic and preclinical data support the oral-cancer prevention potential of green tea extract (GTE). We randomly assigned patients with high-risk oral premalignant lesions (OPLs) to receive GTE at 500 mg/m(2), 750 mg/m(2), or 1000 mg/m(2) or placebo TID for 12 weeks, evaluating biomarkers in...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Prev Res (Phila)
Huvudupphovsmän: Tsao, Anne S., Liu, Diane, Martin, Jack, Tang, Xi-ming, Lee, J. Jack, El-Naggar, Adel K., Wistuba, Ignacio, Culotta, Kirk S., Mao, Li, Gillenwater, Ann, Sagesaka, Yuko M., Hong, Waun K., Papadimitrakopoulou, Vassiliki
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2009
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4243312/
https://ncbi.nlm.nih.gov/pubmed/19892663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-09-0121
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk